Overview

Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

The purpose of the current trial is to evaluate the bioavailability of a single oral dose of naproxen sodium 440 mg and DPH HCL 50 mg under fasting and fed conditions and currently marketed single ingredient products containing naproxen sodium (2 x Aleve® 220 mg tablets) or DPH HCL (2 Allergy Relief x 25 mg tablets) under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Diphenhydramine
Naproxen
Promethazine